Safety, efficacy and pharmacokinetics of peginterferon α2a (40 kd) in children with chronic hepatitis C

Kathleen B. Schwarz, Parvathi Mohan, Michael R. Narkewicz, Jean Molleston, S. Russell Nash, Sylvia Hu, Ka Wang, Jean Michel Gries

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Chronic hepatitis C virus (HCV) infection in children is a problem affecting thousands of children worldwide. Although standard interferon (INF) has better efficacy in pediatric patients than in adults, results in children with genotype 1 are poor; response rates to combination treatment with standard INF and ribavirin are better but the treatment requires thrice-weekly injections. The improved antiviral efficacy of weekly pegylated interferons relative to standard interferons in adults with chronic HCV infection suggests that pegylated interferons may also improve antiviral efficacy in children. We therefore investigated the pharmacokinetics, efficacy and safety of peginterferon α2a (pegINF-α2a) (40 kd) in 14 children ages 2 to 8 years with chronic hepatitis C (13 genotype 1, 1 non-1 genotype). Drug dose was calculated from each patient's body surface area (BSA) according to the formula BSA (m)/(1.73 m) × 180 μg, and patients were administered once-weekly subcutaneous injections for 48 weeks. Viral load and pharmacokinetic parameters were determined from blood drawn throughout the study and during follow-up. At week 24, the mean trough concentration was about 20% below values obtained from adults treated with pegINF-α2a, and the area under the curve from 0 to 168 hours was about 20% above adult values, suggesting that drug doses calculated from BSA achieved therapeutically adequate concentrations. Six of 14 patients (43%), all infected with genotype 1, achieved a sustained virological response. Adverse events were those commonly associated with INF-based treatment, and none was deemed serious. In conclusion, our findings provide a basis for larger studies evaluating the efficacy and safety of pegINF-α2a as monotherapy as well as in combination with ribavirin in pediatric patients with chronic hepatitis C.

Original languageEnglish
Pages (from-to)499-505
Number of pages7
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume43
Issue number4
DOIs
StatePublished - Oct 2006

Fingerprint

chronic hepatitis C
Chronic Hepatitis C
interferons
Interferons
pharmacokinetics
Pharmacokinetics
Safety
Body Surface Area
Genotype
surface area
Hepatitis C virus
genotype
Ribavirin
Virus Diseases
Hepacivirus
Antiviral Agents
Pediatrics
drugs
subcutaneous injection
Subcutaneous Injections

Keywords

  • Body surface area
  • HCV
  • Monotherapy
  • SVR
  • Viral load

ASJC Scopus subject areas

  • Gastroenterology
  • Histology
  • Medicine (miscellaneous)
  • Food Science
  • Pediatrics, Perinatology, and Child Health

Cite this

Safety, efficacy and pharmacokinetics of peginterferon α2a (40 kd) in children with chronic hepatitis C. / Schwarz, Kathleen B.; Mohan, Parvathi; Narkewicz, Michael R.; Molleston, Jean; Nash, S. Russell; Hu, Sylvia; Wang, Ka; Gries, Jean Michel.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 43, No. 4, 10.2006, p. 499-505.

Research output: Contribution to journalArticle

Schwarz, Kathleen B. ; Mohan, Parvathi ; Narkewicz, Michael R. ; Molleston, Jean ; Nash, S. Russell ; Hu, Sylvia ; Wang, Ka ; Gries, Jean Michel. / Safety, efficacy and pharmacokinetics of peginterferon α2a (40 kd) in children with chronic hepatitis C. In: Journal of Pediatric Gastroenterology and Nutrition. 2006 ; Vol. 43, No. 4. pp. 499-505.
@article{e12a34cb17b8435d9d9a13770eb10fec,
title = "Safety, efficacy and pharmacokinetics of peginterferon α2a (40 kd) in children with chronic hepatitis C",
abstract = "Chronic hepatitis C virus (HCV) infection in children is a problem affecting thousands of children worldwide. Although standard interferon (INF) has better efficacy in pediatric patients than in adults, results in children with genotype 1 are poor; response rates to combination treatment with standard INF and ribavirin are better but the treatment requires thrice-weekly injections. The improved antiviral efficacy of weekly pegylated interferons relative to standard interferons in adults with chronic HCV infection suggests that pegylated interferons may also improve antiviral efficacy in children. We therefore investigated the pharmacokinetics, efficacy and safety of peginterferon α2a (pegINF-α2a) (40 kd) in 14 children ages 2 to 8 years with chronic hepatitis C (13 genotype 1, 1 non-1 genotype). Drug dose was calculated from each patient's body surface area (BSA) according to the formula BSA (m)/(1.73 m) × 180 μg, and patients were administered once-weekly subcutaneous injections for 48 weeks. Viral load and pharmacokinetic parameters were determined from blood drawn throughout the study and during follow-up. At week 24, the mean trough concentration was about 20{\%} below values obtained from adults treated with pegINF-α2a, and the area under the curve from 0 to 168 hours was about 20{\%} above adult values, suggesting that drug doses calculated from BSA achieved therapeutically adequate concentrations. Six of 14 patients (43{\%}), all infected with genotype 1, achieved a sustained virological response. Adverse events were those commonly associated with INF-based treatment, and none was deemed serious. In conclusion, our findings provide a basis for larger studies evaluating the efficacy and safety of pegINF-α2a as monotherapy as well as in combination with ribavirin in pediatric patients with chronic hepatitis C.",
keywords = "Body surface area, HCV, Monotherapy, SVR, Viral load",
author = "Schwarz, {Kathleen B.} and Parvathi Mohan and Narkewicz, {Michael R.} and Jean Molleston and Nash, {S. Russell} and Sylvia Hu and Ka Wang and Gries, {Jean Michel}",
year = "2006",
month = "10",
doi = "10.1097/01.mpg.0000235974.67496.e6",
language = "English",
volume = "43",
pages = "499--505",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Safety, efficacy and pharmacokinetics of peginterferon α2a (40 kd) in children with chronic hepatitis C

AU - Schwarz, Kathleen B.

AU - Mohan, Parvathi

AU - Narkewicz, Michael R.

AU - Molleston, Jean

AU - Nash, S. Russell

AU - Hu, Sylvia

AU - Wang, Ka

AU - Gries, Jean Michel

PY - 2006/10

Y1 - 2006/10

N2 - Chronic hepatitis C virus (HCV) infection in children is a problem affecting thousands of children worldwide. Although standard interferon (INF) has better efficacy in pediatric patients than in adults, results in children with genotype 1 are poor; response rates to combination treatment with standard INF and ribavirin are better but the treatment requires thrice-weekly injections. The improved antiviral efficacy of weekly pegylated interferons relative to standard interferons in adults with chronic HCV infection suggests that pegylated interferons may also improve antiviral efficacy in children. We therefore investigated the pharmacokinetics, efficacy and safety of peginterferon α2a (pegINF-α2a) (40 kd) in 14 children ages 2 to 8 years with chronic hepatitis C (13 genotype 1, 1 non-1 genotype). Drug dose was calculated from each patient's body surface area (BSA) according to the formula BSA (m)/(1.73 m) × 180 μg, and patients were administered once-weekly subcutaneous injections for 48 weeks. Viral load and pharmacokinetic parameters were determined from blood drawn throughout the study and during follow-up. At week 24, the mean trough concentration was about 20% below values obtained from adults treated with pegINF-α2a, and the area under the curve from 0 to 168 hours was about 20% above adult values, suggesting that drug doses calculated from BSA achieved therapeutically adequate concentrations. Six of 14 patients (43%), all infected with genotype 1, achieved a sustained virological response. Adverse events were those commonly associated with INF-based treatment, and none was deemed serious. In conclusion, our findings provide a basis for larger studies evaluating the efficacy and safety of pegINF-α2a as monotherapy as well as in combination with ribavirin in pediatric patients with chronic hepatitis C.

AB - Chronic hepatitis C virus (HCV) infection in children is a problem affecting thousands of children worldwide. Although standard interferon (INF) has better efficacy in pediatric patients than in adults, results in children with genotype 1 are poor; response rates to combination treatment with standard INF and ribavirin are better but the treatment requires thrice-weekly injections. The improved antiviral efficacy of weekly pegylated interferons relative to standard interferons in adults with chronic HCV infection suggests that pegylated interferons may also improve antiviral efficacy in children. We therefore investigated the pharmacokinetics, efficacy and safety of peginterferon α2a (pegINF-α2a) (40 kd) in 14 children ages 2 to 8 years with chronic hepatitis C (13 genotype 1, 1 non-1 genotype). Drug dose was calculated from each patient's body surface area (BSA) according to the formula BSA (m)/(1.73 m) × 180 μg, and patients were administered once-weekly subcutaneous injections for 48 weeks. Viral load and pharmacokinetic parameters were determined from blood drawn throughout the study and during follow-up. At week 24, the mean trough concentration was about 20% below values obtained from adults treated with pegINF-α2a, and the area under the curve from 0 to 168 hours was about 20% above adult values, suggesting that drug doses calculated from BSA achieved therapeutically adequate concentrations. Six of 14 patients (43%), all infected with genotype 1, achieved a sustained virological response. Adverse events were those commonly associated with INF-based treatment, and none was deemed serious. In conclusion, our findings provide a basis for larger studies evaluating the efficacy and safety of pegINF-α2a as monotherapy as well as in combination with ribavirin in pediatric patients with chronic hepatitis C.

KW - Body surface area

KW - HCV

KW - Monotherapy

KW - SVR

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=33749509615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749509615&partnerID=8YFLogxK

U2 - 10.1097/01.mpg.0000235974.67496.e6

DO - 10.1097/01.mpg.0000235974.67496.e6

M3 - Article

VL - 43

SP - 499

EP - 505

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 4

ER -